2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

This is not an experiment but a clinical practice guideline. The authors systematically reviewed existing randomised controlled trials, observational studies, and meta-analyses to answer: "What interventions—drugs, lifestyle changes, and risk screening—reduce cardiovascular events (heart attack, stroke, cardiovascular death) in people without established disease (primary prevention) and those with known disease (secondary prevention)?" They tested no single intervention themselves. Instead, they graded the strength of evidence for:

**Lipid-lowering:** Statins (atorvastatin, rosuvastatin, simvastatin) versus placebo or no treatment. Target LDL cholesterol <1.4 mmol/L (≈55 mg/dL) for very-high-risk patients; <1.8 mmol/L (≈70 mg/dL) for high-risk.

**Blood pressure lowering:** Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, thiazides) versus placebo. Target systolic BP <130 mmHg for most adults; <140 mmHg for frail elderly.

**Lifestyle interventions:** Smoking cessation, Mediterranean diet, physical activity (≥150 min/week moderate aerobic), weight loss (≥5% body weight if overweight).

**Risk assessment:** SCORE2 and SCORE2-OP algorithms (10-year risk of fatal/non-fatal CVD) versus older SCORE models.

Outcome measures were major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, cardiovascular death), all-cause mortality, and adverse drug effects.

The guidelines are based on evidence from hundreds of trials and observational cohorts, but the recommendations are intended for:

**Primary prevention:** Adults aged 40–69 without prior CVD, diabetes, or chronic kidney disease (CKD). Sample sizes in the underlying trials range from ~5,000 to ~20,000 per trial (e.g., JUPITER trial: 17,802; HOPE-3: 12,705).

**Secondary prevention:** Adults with prior MI, stroke, revascularisation, or symptomatic peripheral artery disease. Trial populations include ~4,000–18,000 patients (e.g., FOURIER: 27,564; IMPROVE-IT: 18,144).

**Special populations:** Adults ≥70 years (SCORE2-OP derivation cohort: ~600,000 individuals from 25 European cohorts), patients with diabetes (e.g., EMPA-REG OUTCOME: 7,020), and those with CKD (e.g., SHARP: 9,270).

**Excluded from most trials:** Pregnant women, children, patients with terminal illness, those with severe liver or kidney failure, and people on immunosuppressants.

The guidelines did not collect new data. They used standardised outcome definitions from the underlying studies:

**LDL cholesterol:** Measured by enzymatic assay (mmol/L or mg/dL). Target levels derived from meta-regression of statin trials (Cholesterol Treatment Trialists' Collaboration, 2010, 2015).

**Blood pressure:** Office BP measured by automated oscillometric device (mmHg). Home BP monitoring and 24-hour ambulatory BP monitoring recommended for confirmation.

**10-year CVD risk:** SCORE2 algorithm (for ages 40–69) uses age, sex, smoking status, systolic BP, total cholesterol, and HDL cholesterol. SCORE2-OP (for ages 70–89) adds age-specific calibration. Risk categories: low-to-moderate (<5%), high (5–10%), very high (≥10%).

**Lifestyle adherence:** Self-reported via questionnaires (e.g., Mediterranean Diet Adherence Screener, IPAQ for physical activity). No objective biomarkers used in most trials.

**Adverse events:** Myopathy (CK elevation >5x ULN), new-onset diabetes, haemorrhagic stroke, and drug discontinuation rates.

**Design:** Clinical practice guideline developed by the European Society of Cardiology (ESC) using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework. This is not a primary study—it is a systematic synthesis of existing evidence.

**Evidence review:** The authors conducted a systematic literature search of PubMed, Embase, and Cochrane databases up to March 2021. They included:

Randomised controlled trials (RCTs) with ≥1,000 patients and ≥1 year follow-up.

Meta-analyses of RCTs (e.g., Cholesterol Treatment Trialists' Collaboration, Blood Pressure Lowering Treatment Trialists' Collaboration).

Large observational cohorts for risk prediction (e.g., SCORE2 derivation from 45 cohorts in 13 countries).

They excluded case reports, small pilot studies, and non-peer-reviewed sources.

**Grading of recommendations:**

**Class I (strong recommendation):** "Benefit >>> risk." Based on multiple RCTs or meta-analyses with consistent results.

**Class IIa (moderate recommendation):** "Benefit >> risk." Based on one RCT or strong observational data.

**Class IIb (weak recommendation):** "Benefit ≥ risk." Based on expert opinion or limited data.

**Class III (no benefit or harm):** "No benefit or risk > benefit."

**Level of evidence:**

**A:** Data from multiple RCTs or meta-analyses.

**B:** Data from a single RCT or large observational studies.

**C:** Expert opinion or small studies.

**Key methodological features:**

**No randomisation or blinding:** This is a consensus document, not an experiment. The recommendations are based on the average results of trials that were themselves randomised and blinded.

**Duration of underlying trials:** Most statin and BP trials lasted 3–6 years (e.g., JUPITER: median 1.9 years; HOPE-3: 5.6 years; SPRINT: 3.3 years). Lifestyle trials were shorter (6–24 months).

**Statistical approach:** Meta-analyses used fixed- or random-effects models. Risk prediction models used Cox proportional hazards with calibration and discrimination (C-statistic ~0.70–0.75 for SCORE2).

**What this design can and cannot prove:**

**Can prove:** That, on average across large populations, statins reduce MACE by ~25% per 1 mmol/L LDL reduction, and BP lowering reduces MACE by ~20% per 10 mmHg systolic reduction. These are robust, replicated findings.

**Cannot prove:** That any specific individual will benefit. The guidelines are population-level averages. They cannot predict who will experience side effects (e.g., myopathy occurs in ~1 in 10,000 statin users) or who will have zero benefit. They also cannot prove causality for lifestyle interventions because most lifestyle trials are unblinded and rely on self-report.

**Major methodological weaknesses:**

**Publication bias:** Trials with negative results are less likely to be published. The authors attempted to mitigate this by searching trial registries, but it remains a concern.

**Industry funding:** Many of the landmark statin and BP trials were funded by pharmaceutical companies (e.g., JUPITER by AstraZeneca, FOURIER by Amgen). The ESC guidelines declare no direct industry funding for the guideline itself, but the authors have individual conflicts (disclosed in the supplement).

**Population homogeneity:** Most trials enrolled predominantly White European populations. SCORE2 was calibrated for European countries only. Applicability to non-European populations (e.g., South Asian, African, East Asian) is uncertain.

**Short follow-up:** Most trials lasted 3–6 years. The long-term effects (20+ years) of starting statins or BP meds in middle age are extrapolated, not directly observed.

**Lifestyle evidence is weak:** The strongest lifestyle recommendations (e.g., Mediterranean diet, exercise) are based on observational studies and a few small RCTs (e.g., PREDIMED: 7,447 participants, but unblinded). The guidelines downgrade lifestyle recommendations to Class I, Level B or C, reflecting this uncertainty.

**LDL cholesterol reduction:** Each 1 mmol/L (≈39 mg/dL) reduction in LDL with statin therapy reduces major vascular events by ~22% (RR 0.78, 95% CI 0.76–0.80, p<0.0001) over 5 years, regardless of baseline LDL. For very-high-risk patients, targeting LDL <1.4 mmol/L (≈55 mg/dL) reduces events by an additional 15–20% compared with standard targets (e.g., IMPROVE-IT: HR 0.94, 95% CI 0.89–0.99).

**Blood pressure reduction:** Each 10 mmHg reduction in systolic BP reduces MACE by ~20% (RR 0.80, 95% CI 0.77–0.83, p<0.0001). Targeting <130 mmHg versus <140 mmHg reduces MACE by an additional 25% (SPRINT: HR 0.75, 95% CI 0.64–0.89, p=0.001) but increases serious adverse events (hypotension, syncope, acute kidney injury) by ~2%.

**Smoking cessation:** Reduces CVD risk by ~50% within 1–2 years of quitting (observational data, no RCT). The benefit is independent of age or duration of smoking.

**Mediterranean diet:** In PREDIMED (n=7,447, 5-year follow-up), a Mediterranean diet supplemented with extra-virgin olive oil (1 L/week) or nuts (30 g/day) reduced MACE by ~30% (HR 0.70, 95% CI 0.54–0.92, p=0.01) compared with a low-fat diet. However, the trial was unblinded and had high dropout (~11%).

**Physical activity:** ≥150 min/week of moderate aerobic activity (or ≥75 min/week vigorous) reduces CVD mortality by ~25% (observational meta-analysis of 33 studies, n=~500,000, RR 0.75, 95% CI 0.70–0.80). No RCT data exist for this specific dose.

**Weight loss:** ≥5% body weight loss in overweight/obese individuals reduces blood pressure by ~5 mmHg systolic and improves lipid profile (LDL ↓ ~0.2 mmol/L, triglycerides ↓ ~0.3 mmol/L). No trial has tested whether weight loss alone reduces MACE.

**Risk prediction:** SCORE2 reclassifies ~10–15% of intermediate-risk individuals (5–10% 10-year risk) into higher or lower categories compared with older SCORE models, improving net reclassification index by ~0.05–0.10.

**Statins:** If you have a 10-year CVD risk of 10% (i.e., 10 in 100 people like you will have a heart attack or stroke in the next decade), taking a statin for 5 years reduces that to ~7.8%—meaning 2.2 fewer events per 100 people treated. For someone with a 20% risk, it drops to ~15.6% (4.4 fewer events per 100). This is a moderate effect: you need to treat ~45 people for 5 years to prevent one event (number needed to treat, NNT=45).

**BP lowering:** For someone with systolic BP 150 mmHg and 10-year risk 10%, lowering to 130 mmHg reduces risk to ~8% (2 fewer events per 100). NNT=50 over 5 years.

**Lifestyle:** The Mediterranean diet effect (30% relative risk reduction) translates to: if your 10-year risk is 10%, it drops to ~7% (3 fewer events per 100). NNT=33 over 5 years. However, this is based on unblinded data and may be inflated by placebo effects or confounding.

**Smoking cessation:** The 50% risk reduction is dramatic: a 10% risk drops to ~5% (5 fewer events per 100). NNT=20 over 5 years. This is the single most effective intervention.

**Not a primary study:** These are guidelines, not an experiment. The recommendations are only as good as the underlying evidence, which has gaps.

**Population homogeneity:** Most evidence comes from White European men aged 50–70. Women, younger adults, and non-European ethnicities are underrepresented. For example, statin trials enrolled only ~20% women on average.

**Short trial duration:** Most trials lasted 3–6 years. The long-term safety of lifelong statin therapy (starting at age 40) is unknown. Observational data suggest no increase in cancer or non-CVD mortality over 10–15 years, but beyond that, data are sparse.

**Lifestyle evidence is weak:** The strongest lifestyle recommendations (diet, exercise) are based on observational studies and one large but unblinded RCT (PREDIMED). Confounding by socioeconomic status, health literacy, and adherence is likely. The guidelines themselves acknowledge that "the evidence for lifestyle interventions is of lower quality than for pharmacological interventions."

**Side effects are underreported:** Statin-associated muscle symptoms occur in ~5–10% of users in clinical practice but only ~1% in RCTs (due to run-in periods that exclude intolerant patients). The guidelines recommend trying at least two different statins before concluding intolerance, but this advice is based on expert opinion, not trial data.

**Risk prediction is imprecise:** SCORE2 has a C-statistic of ~0.70–0.75, meaning it correctly ranks only ~70–75% of individuals. About 25–30% of people will be misclassified (e.g., labelled high-risk who never have an event, or labelled low-risk who do).

**Industry funding:** Although the ESC guidelines themselves are not industry-funded, many of the landmark trials they cite were. This does not invalidate the findings, but it may bias toward recommending drug therapy over lifestyle (which has no commercial sponsor).

**No individualised guidance:** The guidelines are population-level averages. They cannot tell you whether you personally will benefit from a statin or whether you will experience side effects. For self-experimenters, this means you must test your own response.

For someone running their own n=1 experiment:

### What to test

**Primary prevention:** If you are aged 40–70 and have no known CVD, test whether starting a statin (e.g., atorvastatin 10–20 mg daily) or intensifying lifestyle (Mediterranean diet + 150 min/week exercise) changes your LDL cholesterol, blood pressure, and 10-year SCORE2 risk.

**Secondary prevention:** If you have had a heart attack or stroke, test whether adding ezetimibe (10 mg daily) to your statin further lowers LDL, or whether switching to a high-intensity statin (rosuvastatin 20 mg) is tolerable.

**Lifestyle only:** Test a strict Mediterranean diet (≥1 L/week extra-virgin olive oil, ≥30 g/day nuts, ≥5 servings/day vegetables, ≤2 servings/week red meat) for 6 months. Measure LDL, systolic BP, and body weight monthly.

### Minimum meaningful duration

**Statins:** LDL reduction occurs within 2–4 weeks and stabilises by 6–8 weeks. A meaningful test is 3 months. For event reduction, you need 5+ years, but you can measure surrogate endpoints (LDL, hs-CRP).

**BP meds:** BP reduction occurs within 2–4 weeks. Test for 2–3 months.

**Lifestyle:** LDL and BP changes from diet/exercise appear within 4–8 weeks but may take 3–6 months to plateau. Test for at least 6 months.

**Risk score:** SCORE2 is a 10-year estimate. You cannot measure it in a short experiment, but you can track the inputs (LDL, BP,